Vous êtes ici

Restart Life Sciences Corp.

Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Life Sciences
Symbole: 
HEAL
Indice CSE: 
Devise: 

Restart Life Sciences Corp. is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich Kush dominant cultivars cured to perfection. 

Restart Life Sciences Corp. (HEAL)

(%)

*Financial charts powered by Quotemedia.com. All right reserved. View the Terms of Use. Data delayed 15 minutes unless indicated.

Information d'entreprise

Addresse
700-838 W Hastings Street
Vancouver, BC V6C 0A6
Canada
Téléphone
778-819-0244
Courriel
hello@restartlife.co
URL
https://www.restartlife.co
Date d’inscription à la cote
Mardi, février 10, 2015
Vérificateur
Smythe Ratcliffe LLP

SEDAR Information

Type de dossier Tout
Délai @count semaine@count mois3 month6 month@count annéeTout le temps

Information d'entreprise

Addresse
700-838 W Hastings Street
Vancouver, BC V6C 0A6
Canada
Téléphone
778-819-0244
Courriel
hello@restartlife.co
URL
https://www.restartlife.co
Date d’inscription à la cote
Mardi, février 10, 2015
Vérificateur
Smythe Ratcliffe LLP

Capitalisation

Capitalisation: 
33230355
Réservé à l'émission: 
14023708

Company Officers

Steve Loutskou, Chief Executive Officer
Kelly Pladson, Corporate Secretary
Rebecca Hudson, Chief Financial Officer
Derek Ivany, Executive Chair

Bulletins

22/01/2025

2025-0115 - Consolidation - Restart Life Sciences Corp. (HEAL)

le 22 janvier/January 2025

Restart Life Sciences Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every two (2) pre-consolidated common shares.

As a result, the number of outstanding shares will be reduced to approximately 18,126,950 common shares.

The name and symbol will not change.